Fatigue, which is one of the most commonly reported symptoms in cancer, can negatively impact the functional status and the health-related quality of life of individuals. This paper systematically reviews 34 studies to determine patterns of associations between immunogenomic markers and levels of cancer-related fatigue (CRF). Findings from the longitudinal studies revealed that elevated fatigue symptoms especially of women with early stages of breast cancer were associated with high levels of neutrophil/ monocyte, IL-1ra, and IL-6 during radiation therapy; high levels of CD4+, IL-1b, and IL-6 with stressing stimuli; high levels of IL-1b during chemotherapy; low NK cell levels after chemotherapy; and presence of homozygous IL-6 and TNF alleles. In the cross-sectional studies, associations between levels of fatigue and immune/inflammatory markers were not consistently found, especially when covariates such as BMI, ethnicity, menopausal status, and educational level were controlled in the statistical analyses. However, a number of genomic markers were observed to be elevated mostly in fatigued breast cancer survivors in the cross-sectional studies. Gaps in knowledge and recommendations for future research are discussed.
Introduction
Advances in cancer treatment have led to high survival rates and prolonged the natural history of the disease. However, improved survival rates are mitigated by symptoms associated with treatments that lower the health-related quality of life (HRQOL) for survivors. Fatigue is one of the most commonly reported symptoms in cancer with a prevalence rate of 59% to 100% depending on the clinical status of the disease (Weis, 2011).
Cancer-related fatigue (CRF) is defined as a ''distressing, persistent subjective sense of tiredness or exhaustion related to cancer or cancer treatment that is not proportional to recent activity and that interferes with usual functioning '' (Berger et al., 2010, p. 906) . CRF considerably impacts the functional status and HRQOL of individuals by imposing physical limitations and psychological impairments (Curt et al., 2000) . Although studies have been conducted to identify associations between immune and inflammatory markers with the severity and intensity of CRF, no causation between a specific biomarker and CRF has been established, contributing to its inadequate clinical management.
The diversity of factors that predispose to CRF suggests that it is a multidimensional symptom that has common related molecular pathways with multiple contributory mechanisms (Miakowski, 2002) . The current understanding about the etiology of CRF is based on limited evidence that environmental, genetic, psychological, and physiological factors play important roles in the impairment of oxygen supply, neuromuscular signaling, and the hypothalamus-pituitary-adrenal axis functioning. The goal of this literature review was to systematically review studies that evaluated immunogenomic markers and CRF in order to identify patterns of associations between these variables.
Methods
An initial generic search in PubMed (any date) using the following key words, ''Fatigue AND cancer ''[title] 
